ホーム › 卵巣がん › コロンビア特別区 › Washington
Washington、DCにおける卵巣がんの臨床試験
Washingtonとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する23件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Walter Reed National Military Medical Center, Bethesda · 7マイル先
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Walter Reed National Military Medical Center, Bethesda · 7マイル先
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
被験者募集中第1相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
被験者募集中第2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
被験者募集中第1相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- Holy Cross Hospital /ID# 275872, Silver Spring · 7マイル先
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
被験者募集中第2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
被験者募集中第3相
- MedStar Washington Hospital Center ( Site 0026), Washington D.C.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Georgetown University Medical Center, Washington D.C.
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- Holy Cross Hospital, Silver Spring · 7マイル先
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第2相
- Medstar Georgetown University Hospital, Washington D.C.
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
被験者募集中第3相
- Holy Cross Hospital, Silver Spring · 7マイル先
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Children's National Medical Center, Washington D.C.
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
被験者募集中第1相
- Normunity Investigational Site, Washington D.C.
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
被験者募集中第1/2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
被験者募集中第2相
- USA11-0, Bethesda · 7マイル先
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
被験者募集中第2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
被験者募集中観察研究健康なボランティア歓迎
- Cancer Support Community Research & Training Institute, Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Silver Spring · 7マイル先
- Massive Bio SYNERGY-AI site, Bethesda · 7マイル先
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
被験者募集中健康なボランティア歓迎
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
被験者募集中第1相
- Holy Cross Hospital, Silver Spring · 7マイル先
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
Washingtonにおける他の研究
- がん（全種類）58件の研究
- 非小細胞肺癌55件の研究
- 乳がん46件の研究
- 転移性癌43件の研究
- 肺がん41件の研究
- 前立腺がん38件の研究
- 肥満症33件の研究
- 大腸癌29件の研究
- 心血管疾患28件の研究
- 膀胱癌26件の研究
- 急性骨髄性白血病24件の研究
- リンパ腫23件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。